Paroxetine efficacy in the treatment of generalized anxiety disorder

@article{Rocca1997ParoxetineEI,
  title={Paroxetine efficacy in the treatment of generalized anxiety disorder},
  author={Paola Rocca and Valeria Fonzo and M. Scotta and Enrico Zanalda and Luigi Ravizza},
  journal={Acta Psychiatrica Scandinavica},
  year={1997},
  volume={95}
}
Recently, there has been a renewed interest in alternatives to the benzodiazepines for the treatment of generalized anxiety disorder (GAD). The aim of the present study was to compare the efficacy of paroxetine vs. imipramine and 2′‐chlordesmethyldiazepam in 81 patients with a DSM‐IV diagnosis of GAD. Approximately two‐thirds of the patients who completed the study improved greatly or moderately on all three active drugs. During the first 2 weeks of treatment, 2′‐chlordesmethyldiazepam… 

Paroxetine in the treatment of generalised anxiety disorder

Antidepressants, such as paroxetine, are more effective for the psychic symptoms of anxiety, which include worry, tension, irritability and concentration difficulties, and carry a more tolerable and safe side effect profile.

Efficacy of Adepress (paroxetine) in Generalized Anxiety Disorder

Adepress was effective in both isolated GAD and GAD complicated by comorbid mental pathology, and when somatic anxiety dominated the structure of GAD, treatment effects with Adepress started at treatment weeks 3–4.

Generalised Anxiety Disorder

In the search for the ideal anxiolytic, a more positive outlook is allowed by imminent future research for new treatment options in patients with GAD.

Paroxetine treatment of generalized anxiety disorder.

Results of randomized, controlled studies of paroxetine have demonstrated its efficacy in the short-term treatment of GAD, in achieving and sustaining full remission, and in preventing relapse.

Pharmacotherapy of generalized anxiety disorder.

  • J. Davidson
  • Psychology, Medicine
    The Journal of clinical psychiatry
  • 2001
Treatment with antidepressants has opened up a new area of investigation into the pharmacotherapy of GAD, with a growing body of evidence supporting the role of therapies such as paroxetine and venlafaxine extended release.

Evidence-based pharmacotherapy of Generalized Anxiety Disorder.

Due to their efficacy in GAD and comorbid anxiety and depressive disorders, their tolerability and safety, certain selective serotonin re-uptake inhibitors (escitalopram, paroxetine, sertraline) should be considered the first-line treatment for most patients, although the serotonin-noradrenaline re-ptake inhibitor venlafaxine is a reasonable alternative.

Pharmacologic Treatments Effective in Both Generalized Anxiety Disorder and Major Depressive Disorder: Clinical and Theoretical Implications

Alprazolam, at doses double those generally recommended for anxiety disorders, appears to be as effective as tricyclic antidepressants (TCAs) in the acute treatment of mild to moderate MDD and the nonspecificity of treatment response suggests that GAD and MDD are different expressions of a similar disorder with a common neurobiological substrate.

Long term therapy of generalized anxiety disorder

[Pharmacological treatment of generalized anxiety disorders: rationale and limitations].

It is important to realize that most clinical trials in this field only include patients with non-comorbid generalized anxiety and that their conclusion may not always be generalizable to most psychiatric patients who are usually characterized by a high rate of comorbidity.

Paroxetine: an update of its use in psychiatric disorders in adults.

Given the high degree of psychiatric comorbidity of depression and anxiety, paroxetine is an important first-line option for the treatment of major depressive disorder, OCD, panic disorder, social anxiety disorder, GAD and PTSD.
...

References

SHOWING 1-10 OF 31 REFERENCES

Differential effects of alprazolam and imipramine in generalized anxiety disorder: somatic versus psychic symptoms.

In generalized anxiety, somatic symptoms and hyperarousal selectively respond to drugs acting on the gamma-aminobutyric acid system, whereas psychic symptoms respond to treatments affecting the noradrenergic or serotonergic systems.

Antidepressants for the treatment of generalized anxiety disorder. A placebo-controlled comparison of imipramine, trazodone, and diazepam.

The results of the study need replication, but suggest a potentially important role for antidepressants, particularly imipramine, in patients suffering from GAD.

Drug treatment of obsessive-compulsive disorder (OCD): long-term trial with clomipramine and selective serotonin reuptake inhibitors (SSRIs).

A 2-year, open-label followup was performed on 130 obsessive-compulsive patients who were responders to a previous 6-month treatment with clomipramine, fluoxetine, or fluvoxamine and maintenance treatments were found significantly superior to discontinuation in preventing relapses.

Alprazolam in panic disorder and agoraphobia: results from a multicenter trial. I. Efficacy in short-term treatment.

Alprazolam was found to be effective and well tolerated in patients with agoraphobia with panic attacks and panic disorder and significantly more placebo recipients subsequently dropped out of the trial, primarily citing ineffectiveness of placebo as the reason.

Imipramine and chlordiazepoxide in depressive and anxiety disorders. II. Efficacy in anxious outpatients.

Excluding patients with possible panic-phobic syndromes from the analyses removed most significant antiphobic and antidepressant effects of imipramine but left intact imipramsine's significantly superior antianxiety effects.

Obsessive-compulsive disorder. A double-blind trial of clomipramine and clorgyline.

Patients with obsessive-compulsive disorder who met DSM-III criteria and who had been ill for at least one year were studied in a double-blind, randomized, crossover comparison of the tricyclic

Neurotic illness and its response to anxiolytic and antidepressant treatment

It is concluded that a distinction between anxiety and depression in neurotic out-patients is of no practical value with regard to drug treatment.

Long-term diazepam therapy and clinical outcome.

It is indicated that a significant number of patients benefit from prolonged diazepam treatment and that tolerance to the anxiolytic effect of diazepAM does not develop during a 22-week study period.

The SSRIs: advantages, disadvantages and differences

The highly specific mechanism of action of the selective serotonin re-uptake inhibitors (SSRIs) confers advantages on this group, relative to other classes of antidepressant, and thus represents a

Controlled comparison of bromazepam, amitriptyline, and placebo in anxiety-depressive neurosis.

  • E. Shammas
  • Psychology, Medicine
    Diseases of the nervous system
  • 1977
The prompt clinical response to bromazepam contributed to its superior safety and patient progress in that it was possible to carefully titrate dosage and thus help to control adverse reactions and allow patients to maintain alertness and productivity under therapy.